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Nitric oxide– and EDHF-mediated arteriolar tone in uremia is
unaffected by selective inhibition of vascular cytochrome P450
2C9.
Background. Uremia is a state of endothelial dysfunction
as demonstrated by a reduced agonist-induced endothelium-
dependent vasodilatation. Recent studies suggest that an en-
dothelial cytochrome P450 (CYP) epoxygenase (CYP 2C9)
can modulate endothelium-dependent vasodilatation in two
different ways: (1) by the production of epoxyeicosatrienoic
acids (EETs), which elicit hyperpolarization and relaxation; and
(2) by the release of oxygen-derived free radicals, which com-
promise the bioavailability of nitric oxide. We therefore deter-
mined whether one of these pathways is involved in endothelial
dysfunction of uremia.
Methods. Using venous occlusion plethysmography, we mea-
sured forearm blood flow (FBF) in response to the intrabrachial
infusion of acetylcholine (ACh; endothelium-dependent va-
sodilator; 1, 5, 10, 50, 100, and 300 nmol/min) and sodium ni-
troprusside (SNP; endothelium-independent vasodilator; 2.5,
5 and 10 lg/min) in 10 stable patients on hemodialysis (HD)
and 9 healthy control subjects. In HD patients, ACh infusions
were repeated together with sulfaphenazole (SPZ, 6 mg/min),
a highly selective inhibitor of CYP 2C9 with and without
concomitant blockade of the nitric oxide synthase (NOS) by
Nxmonomethyl L-arginine (L-NMMA, 16 lmol/min).
Results. Endothelium-dependent vasodilatation to ACh was
reduced in HD compared to control subjects (P = 0.002),
indicating endothelial dysfunction in the patients examined.
Endothelium-independent vascular responses to SNP were at-
tenuated in HD, but not significantly different to control. SPZ
failed to modulate both baseline FBF and Ach-induced vasodi-
latation in HD. Furthermore, SPZ had no effect on baseline FBF
and ACh-mediated vasodilatation in the presence of L-NMMA
in HD.
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Conclusion. Our results do not support a major role for CYP
2C9-derived products in the regulation of arteriolar tone in early
endothelial dysfunction of uremic subjects.
Endothelial dysfunction, a term that refers to atten-
uated agonist-induced endothelium-dependent vasodi-
latation, is regarded as an early sign of atherosclerosis
[1], and has been shown to be a significant predictor
of future cardiovascular events [2, 3]. Uremia is associ-
ated with excessive cardiovascular morbidity and mor-
tality [4], and impaired endothelial function has been
demonstrated in uremic patients [5–7]. Understanding
the mechanisms underlying uremia-associated endothe-
lial dysfunction may be important for future therapeutic
interventions.
Agonist-induced, endothelium-dependent vasodilata-
tion is in part mediated by the generation of nitric ox-
ide (NO) and prostacyclin (PGI2). A substantial portion
of this response is, however, resistant to the combined
blockade of the nitric oxide synthases (NOS) and cy-
clooxygenases. Because NO/PGI2–independent vasodi-
latation is associated with hyperpolarization of vascular
smooth muscle cells, it has been attributed to the re-
lease of an endothelium-derived hyperpolarizing factor
(EDHF). The term EDHF does not represent a single hy-
perpolarizing factor that is a distinct chemical identity, but
seems to encompass a number of mechanisms linked to
smooth muscle hyperpolarization and relaxation [8]. Al-
though a CYP 2C epoxygenase is the source of vascular
smooth cells hyperpolarizing epoxyeicosatrienoic acids
(EETs) in porcine coronary arteries [9] and human mam-
mary arteries [10], this enzyme is also able to generate re-
active oxygen species, which interfere with the bioavail-
ability of NO and, thus, interfere with NO-mediated
vasodilatation and the expression of redox-sensitive
genes [11]. The latter mechanism appears to dominate in
1907
1908 Passauer et al: Cytochrome P450 in uremia
situations of endothelial dysfunction since a consid-
erable improvement in the acetylcholine-induced NO-
dependent vasodilatation of the forearm vasculature was
recorded in patients with coronary heart disease when
CYP 2C9 was inhibited [12].
Uremia is a state of endothelial dysfunction, as shown
by a reduced agonist-induced endothelium-dependent
vasodilation [7, 13]. The aim of the present study was,
therefore, to determine whether a CYP 2C9 product
(either 11,12 EET or oxygen-derived free radicals) has
a modulating effect on endothelium-dependent vasodi-
latation in patients on hemodialysis.
METHODS
Subjects
The study protocol was approved by the University of
Dresden ethics committee. Ten stable, nondiabetic male
patients on regular hemodialysis (HD), and 9 healthy
volunteers matched for age, gender, height, weight, and
smoking habits were recruited, and written informed con-
sent was obtained before any investigation was started.
All HD patients enrolled were on a transplant waiting
list. Physical examination, ECG, exercise testing, and
laboratory screening were performed regularly in this
context and revealed no evidence of clinically relevant
atherosclerotic disease. HD patients had mild hyperten-
sion requiring drug treatment (beta-blockers N = 4, ACE
inhibitors N = 4, calcium antagonists N = 2). Antihyper-
tensive medication was withdrawn 48 hours before the
start of the study. HD patients were studied in the morn-
ing during their short dialysis-free interval. Their actual
weight did not exceed the estimated dry weight by more
than 2 kg. In healthy control subjects, hypertension or un-
derlying vascular disease was ruled out by physical exam-
ination. Cigarettes, alcohol, and all caffeine-containing
beverages were withheld for 12 hours before the study.
All investigations were performed in a quiet room kept at
a constant temperature of between 22◦C and 24◦C. Each
subject was supine, with both forearms resting slightly
above heart level.
Measurement of forearm blood flow (FBF)
FBF was measured simultaneously in both arms by
venous occlusion plethysmography as described previ-
ously [7]. In HD patients, only the arm not bearing the
arteriovenous fistula was available for FBF recordings.
Pressure of the congesting cuffs of both upper arms
was set at 40 mm Hg. Mercury-in-silastic strain gauges
were wrapped around the widest parts of the forearms
and connected to a calibrated venous occlusion plethys-
mograph (Gutmann Medizinelektronik, Eurasburg,
Germany). The brachial artery of the nondominant
arm (or the arm without arteriovenous fistula, respec-
tively) was cannulated with a 27-G steel needle (Coopers
Needle Work, Birmingham, UK) for drug infusion. After
cannulation of the brachial artery, saline was infused for
20 minutes to establish baseline conditions in each proto-
col. Individual measurements of FBF lasting 10 seconds
were made every 15 seconds for 2.5 minutes during each
dose of agent administered. The blood flow of the hands
was excluded by a wrist cuff inflated to a suprasystolic
pressure (220 mm Hg) during each measurement period.
Blood pressure was measured at baseline and at the end of
each infusion period. During each protocol, the infusion
rate was kept constant at 1 mL/minute. Blood pressure
was measured supine before arterial cannulation on the
infusion arm using a Dinamap Pro 200 (Criticon, Tampa,
Mexico). At the end of each FBF determination, blood
pressure was measured at the left arteria dorsalis pedis.
Experimental protocols
The study consisted of 2 different experimental proto-
cols. One hour before each protocol participants received
1200 mg ibuprofen orally. This dose has been used previ-
ously to inhibit endothelial PGI2 production [14].
Protocol 1: Influence of sulfaphenazole on baseline FBF
and on acetylcholine-induced endothelium-dependent
vasodilation (HD, N = 10; control, N = 9)
Acetylcholine was infused at increasing doses of 1, 5,
10, 50, 100, and 300 nmol/min, and FBF measurements
were obtained at the end of each dosing period (5 min-
utes). We used this wide dose range of acetylcholine
because dose-dependent differences in the generation of
nitric oxide and EDHF in response to the drug have been
observed [15]. After a resting period of 30 minutes to
reestablish baseline FBF, sulfaphenazole was infused at
2 mg/min over 10 minutes and FBF measurements were
obtained. Sulfaphenazole is a highly specific inhibitor of
CYP 2C9, and inhibits enzyme activity and reactive oxy-
gen species generation by a microsomal preparation from
CYP 2C9 overexpressing cells with an IC50 of approx-
imately 2 lmol/L [16]. We have previously shown that
this dose of sulfaphenazole results in plasma concentra-
tions of 50 to 180 lmol/L in the forearm under base-
line conditions [17]. We gave this apparently high dose
to account for the considerable protein binding of the
drug, which is reported to be between 98% and 100%.
Comparable doses have been used to attenuate exercise-
induced vasodilatation in healthy subjects [18], and to
improve endothelium-dependent vasodilatation in pa-
tients with coronary heart disease [12]. In HD patients,
sulfaphenazole was increased to 6 mg/min, and continued
during subsequent infusion of acetylcholine as described
above. The dose of sulfaphenazole was increased to main-
tain the desired plasma concentration during infusion of
acetylcholine.
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Protocol 2: Influence of sulfaphenazole on baseline FBF
and on acetylcholine-induced endothelium-dependent
vasodilatation in the presence of Nxmonomethyl
L-arginine (L-NMMA; HD, N = 7)
L-NMMA (16 lmol/minute) was infused over 10 min-
utes. This dose has been shown to mediate maximal in-
hibition of both baseline and stimulated vascular nitric
oxide synthesis in the forearm [15]. After FBF measure-
ments, acetylcholine was added as described in protocol
1. After a 30-minute washout-period of saline infusion,
L-NMMA (16 lmol/minute) was started again and
FBF was measured after 10 minutes. Thereafter, sul-
faphenazole (2 mg/minute) was coinfused for 10 min-
utes, and FBF recordings were repeated. L-NMMA
(16 lmol/minute) and sulfaphenazole (6 mg/min) were
continued, and acetylcholine was added as shown
before.
In a third experimental session (performed in all par-
ticipants on a separate day) we tested endothelium-
independent vasodilatation using graded infusions of
sodium nitroprusside at 2.5, 5, and 10 lg/min. Assess-
ment of endothelium-independent vasodilatation was
completed by determination of peak FBF after 5 min-
utes of forearm ischemia in a further experimental
session.
Drugs
Ibuprofen (Jenaprofen) was obtained from
Jenapharm (Jena, Germany); L-NMMA and the
sodium acetate salt of sulfaphenazole were from Clinalfa
(La¨ufelfingen, Switzerland); acetylcholine (Miochol E)
was obtained from Ciba Vision (Germering, Germany);
and sodium nitroprusside (nipruss) was from Schwarz
Pharma (Monheim, Germany). All agents used were
dissolved in physiologic saline except for sodium nitro-
prusside, which was dissolved in glucose 5%, avoiding
exposure to light.
Statistics
FBF is expressed either as an absolute value (mL
per dL of forearm tissue per minute) or the difference
( FBF) between the absolute FBF during drug infusion
and the FBF measured before drug infusion. One FBF
determination consisted of 10 single FBF measurements.
The final 5 blood flow recordings for each infusion step
were used to calculate mean FBF. Results are presented
as mean ± SEM. Comparison of group characteristics and
vascular responses to sulfaphenazole at rest were per-
formed using the Student t test. Dose-response curves
to acetylcholine and sodium nitroprusside were analyzed
by two-way analysis of variance (ANOVA) for repeated
measurements. Values of P < 0.05 were considered sta-
tistically significant.
Table 1. Baseline characteristics of hemodialysis patients (HD) and
control subjects
HD Control
Characteristic (N = 10) (N = 9) P value
Age years 37 ± 4 36 ± 3 0.91
Height cm 175 ± 3 172 ± 2 0.33
Weight kg 69 ± 3 70 ± 3 0.70
Active smokers N = 3 N = 3
Systolic BP mm Hg 146 ± 6 129 ± 3 0.02
Diastolic BP mm Hg 80 ± 2 67 ± 2 0.003
Mean BP mm Hg 101 ± 4 86 ± 3 0.008
Total cholesterol mmol/L 4.2 ± 0.2 4.4 ± 0.2 0.36
Time on HD years 6.6 ± 1.5
Values represent mean ± SEM.
RESULTS
Arterial puncture was performed without complica-
tions in all subjects. Substances were tolerated well by
all participants. Blood pressure and heart rate remained
stable in each individual during all experimental sessions
(data not shown). FBF in the noninfused arm (which
could be assessed in control subjects only) was constant
during each experimental protocol (data not shown).
Baseline characteristics of the subjects participating in
each group are given in Table 1.
Effect of sulfaphenazole on baseline FBF
Infusion of sulfaphenazole into the resting forearm vas-
cular bed resulted in a small but insignificant increase in
FBF in both HD (from 3.4 ± 0.7 to 3.8 ± 0.7 mL/dL × min;
P = 0.65) and control (from 1.8 ± 0.2 to 2.0 ± 0.3;
P = 0.30).
Endothelium-dependent and endothelium-independent
vasodilation
Baseline FBF before infusion of acetylcholine was
3.8 ± 0.5 mL/dL × min in HD and 2.5 ± 0.4 in control.
Endothelium-dependent vasodilatation in response to in-
creasing doses of acetylcholine was significantly reduced
in HD compared to control (P = 0.002 by ANOVA), as
outlined in Figure 1A.
Baseline FBF before infusion of sodium nitroprusside
was 2.9 ± 0.4 mL/dL × min in HD and 3.0 ± 0.4 in con-
trol. Endothelium-independent vasodilatation mediated
by this drug tended to be lower in HD; however, this
difference did not reach statistical significance (P = 0.14
by ANOVA). Results are illustrated in Figure 1B. Appli-
cation of 5 minutes of forearm ischemia increased FBF
from 3.0 ± 0.4 to 16.1 ± 1.3 in HD, and from 3.0 ± 0.7
to 17.7 ± 1.6 mL/dL × min in control. These results were
statistically not different (P = 0.51 by ANOVA).
Effect of sulfaphenazole on acetylcholine-induced
endothelium-dependent vasodilatation in HD
Baseline FBF was identical before infusion of acetyl-
choline alone or acetylcholine in combination with
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Fig. 1. (A) Acetylcholine-mediated endo-
thelium-dependent vasodilatation in pa-
tients on hemodialysis (HD) and con-
trol subjects. ∗P < 0.01 by ANOVA.
(B) Endothelium-independent vasodilatation
induced by sodium nitroprusside. Vascular re-
sponse tended to be lower in HD; the differ-
ence did not reach significance.
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Fig. 2. Effect of sulfaphenazole on acetylcholine-induced endothe-
lium-dependent vasodilatation in 10 patients on hemodialysis.
sulfaphenazole, being 3.8 ± 0.5 mL/dL × min. Coin-
fusion of sulfaphenazole had no modulating effect on
acetylcholine-mediated vascular responses in HD (P =
0.55 by ANOVA), as shown in Figure 2.
Effect of sulfaphenazole on baseline FBF in the presence
of L-NMMA in HD
Baseline FBF in the presence of L-NMMA was 1.7 ±
0.3 mL/dL × min. Infusion of sulfaphenazole had no mea-
surable effect on FBF (1.7 ± 0.3; P = 0.77).
Effect of sulfaphenazole on acetylcholine-induced
endothelium-dependent vasodilatation in the presence of
L-NMMA in HD
Before infusion of acetylcholine, baseline FBF was
2.3 ± 0.3 mL/dL × min in the presence of L-NMMA
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Fig. 3. Effect of sulfaphenazole on acetylcholine-induced endothe-
lium-dependent vasodilatation in the presence of L-NMMA in 7
patients on hemodialysis.
alone, and 1.7 ± 0.3 in the presence of both L-NMMA
and sulfaphenazole. Sulfaphenazole had no modulat-
ing effect on acetylcholine-induced NO/PGI2–resistant
endothelium-dependent vasodilatation (P = 0.60 by
ANOVA), as demonstrated in Figure 3.
DISCUSSION
This study was conducted to test the hypothesis that
in uremic patients an endothelial CYP 2C9–dependent
enzyme acts as a significant source of oxygen-derived
free radicals (compromising the bioavailability of vascu-
lar NO) and/or 11,12-EET (which may act as an EDHF).
We found that in HD patients with proven endothelial
dysfunction, the inhibition of CYP 2C9 by sulfaphenazole
had no effect on both baseline FBF and on acetylcholine-
mediated endothelium-dependent vasodilatation.
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Previous studies have demonstrated that in the fore-
arm circulation of healthy humans, CYP 2C9–dependent
products are not involved in the regulation of vas-
cular tone. This was primarily shown by the fact
that sulfaphenazole, a highly specific inhibitor of CYP
2C9, had no effect on baseline FBF [17]. In addition,
sulfaphenazole did not modulate bradykinin-induced
NO/PGI2–independent [17] and acetylcholine-induced
NO-dependent vasodilation [12] in control subjects. It
is conceivable, however, that the sensitivity to this sul-
fonamide is increased in patients demonstrating a man-
ifest endothelial dysfunction. Nitric oxide interacts with
hemoproteins, such as CYP, to inhibit enzyme activity. It
follows that a decrease in the bioavailability of NO (as
in endothelial dysfunction) could be associated with an
increase in CYP activity.
Our results demonstrate that sulfaphenazole does not
significantly affect resting FBF in either the absence or
presence of L-NMMA. We conclude that CYP 2C9–
derived products do not contribute to baseline arterio-
lar tone in the forearm in HD patients. This observation
is not too surprising as it is generally accepted that the
activation of CYP enzymes is a Ca2+-dependent process,
requiring the activation of phospholipase A2 to liberate
the CYP 2C substrate, arachidonic acid, from membrane
phospholipids.
However, the results obtained during infusion of
acetylcholine in protocol 1 demonstrate that the im-
pairment of endothelium-dependent vasodilatation ob-
served in HD patients cannot be improved by block-
ade of CYP 2C9. Generally, the presence of increased
oxidative stress, resulting in an inactivation of nitric ox-
ide in uremia, has been suggested by various studies
[19, 20]. These results were further substantiated by the
observation that the antioxidant vitamin C improves
endothelium-dependent vasodilatation, at least at the
level of arterial resistance vessels, in patients with renal
failure [21]. Our finding therefore suggests that CYP 2C9
does not substantially contribute to breakdown of NO
and, hence, to endothelial dysfunction in HD patients.
This observation is in contrast to the recent report by
Fichtlscherer et al, who demonstrated a substantial im-
provement of NO-mediated endothelium-dependent va-
sodilation in patients with coronary artery disease [12].
One explanation for this discrepancy might be that CYP
2C9 activation is more pronounced in subjects with ad-
vanced atherosclerosis (which was clearly not present in
our patients). Another explanation could be that in ure-
mia, agonist-stimulated NO synthesis, per se, is reduced
(e.g., by endogenous NOS inhibitors or by uncoupling of
NOS).
Another important question of our investigation was
whether CYP 2C9 could be a source of an EDHF in a
sense of a “backup” mechanism in response to reduced
bioavailability of nitric oxide, as suggested by previous
studies (reviewed in [22]). The results obtained in pro-
tocol 2 demonstrate that sulfaphenazole does not affect
acetylcholine-mediated NO/PGI2- independent vasodi-
latation, indicating that this pathway is not prominent in
the forearm vasculature of HD patients.
CONCLUSION
Activation of CYP 2C9 is not involved in early arteri-
olar endothelial dysfunction of uremic subjects. Our ob-
servations may indicate that blood pressure regulation
does not critically depend on endothelial expression of
CYP 2C9 in this setting. We cannot rule out that such a
pathway plays a role in conduit vessels and/or later in the
process of atherogenesis in uremia. These questions may
be subject to further studies.
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